CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Yung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, Toshihiko Doi

Cancer Research and Treatment. 2018;50(2):398-404. Published online 2017 May 10 DOI: https://doi.org/10.4143/crt.2017.074

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Yung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, Toshihiko Doi

Cancer Research and Treatment. 2018;50(2):398-404

Link1

Link2 Link3

Phase I Study of the Investigational Anti-Guanylyl Cyclase C (GCC) Antibody-Drug Conjugate (ADC) Mln0264 in Adult Patients with Advanced Gastrointestinal Malignancies Expressing GCC

J.E. Faris, C. Cruz, K. Almhanna, W. Messersmith, J. Rodon, D.P. Ryan, J.A. Jung, A. Fasanmade, T. Wyant, T. Kalebic

Annals of Oncology. 2014;25:ii108

Link1 Link2 Link3

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

Khaldoun Almhanna, David Wright, Teresa Macarulla Mercade, Jean-Luc Van Laethem, Antonio Cubillo Gracian, Carmen Guillen-Ponce, Jason Faris, Carolina Muriel Lopez, Richard A. Hubner, Johanna Bendell, Alain Bols, Jaime Feliu, Naureen Starling, Peter Enzinger, Devalingham Mahalingham, Wells Messersmith, Huyuan Yang, Adedigbo Fasanmade, Hadi Danaee, Thea Kalebic

Investigational New Drugs. 2017;35(5):634-641

Link1 Link2

Link3

81P Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)

I-H. Kim

Annals of Oncology. 2022;33:S1464

Link1 Link2

Mln0264, an Investigational, First-In-Class Antibody-Drug Conjugate Targeting Guanylyl Cyclase C (Gcc): First-In-Human Study in Patients with Advanced Gastrointestinal Malignancies

Wells Messersmith, Khaldoun Almhanna, Jordi Rodon, Cristina Cruz, David Ryan, JungAh Jung, Adedigbo Fasanmade, Tim Wyant, Thea Kalebic

Annals of Oncology. 2013;24:iv36

Link1 Link2 Link3

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

Khaldoun Almhanna, Maria Luisa Limon Miron, David Wright, Antonio Cubillo Gracian, Richard A. Hubner, Jean-Luc Van Laethem, Carolina Muriel López, Maria Alsina, Frederico Longo Muñoz, Johanna Bendell, Irfan Firdaus, Wells Messersmith, Zhan Ye, Adedigbo A. Fasanmade, Hadi Danaee, Thea Kalebic

Investigational New Drugs. 2017;35(2):235-241

Link1

Link2 Link3

P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers

K. Muro, J. Bruce, J. Baranda, S. Gorla, C. Wu, F. Braiteh

Annals of Oncology. 2021;32:S130

Link1 Link2

Denosumab in Patients with Metastatic Prostate Cancer Previously Treated with Denosumab or Zoledronic Acid: 2-Year Open-Label Extension Phase Results from the Pivotal Phase 3 Study

K. Fizazi, J.E. Brown, M. Carducci, N.D. Shore, P. Sieber, F. Kueppers, L. Karsh, R. Wei, C. Goessl

Annals of Oncology. 2012;23:ix309

Link1 Link2

Iron parameters in patients with end-stage renal disease receiving lanthanum carbonate or other non-iron-based phosphate binders: Results from a phase 3, randomized open-label study

Rosamund J Wilson, Beverly Jones, Claudio Marelli

SAGE Open Medicine. 2018;6:205031211878616

Link1 Link2 Link3

EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)

D.P. Petrylak, J. Rosenberg, I. Duran, Y. Loriot, G. Sonpavde, C. Wu, E. Gartner, A. Melhem-Bertrandt, T. Powles

Annals of Oncology. 2018;29:viii328

Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.